Silexion Therapeutics shares are trading higher after the company announced findings from its Phase 2 trial of LODER in patients with non-resectable locally advanced pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Silexion Therapeutics shares rose following positive results from its Phase 2 trial of LODER for non-resectable locally advanced pancreatic cancer.
September 24, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silexion Therapeutics shares increased due to positive Phase 2 trial results of LODER, a treatment for non-resectable locally advanced pancreatic cancer.
The positive trial results are likely to boost investor confidence in Silexion Therapeutics, as successful clinical trials can lead to future revenue from drug sales. This news directly impacts SLXN's stock price positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100